X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12, 2022

03 May 2022 05:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 May 2022 15:05:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022

08 Apr 2022 12:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at April Investor Conferences

04 Apr 2022 07:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Apr 2022 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

17 Mar 2022 05:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022

08 Mar 2022 07:00:03 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at March Investor Conferences

03 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2022 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference

19 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jan 2022 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

13 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

11 Dec 2021 08:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor

02 Dec 2021 05:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2021 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Stifel’s Virtual Healthcare Conference

10 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results

04 Nov 2021 08:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2021 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

25 Oct 2021 07:00:01 By Nasdaq GlobeNewswire